- Trial phase
- Approved (genericized / off-patent legacy brand)
- Time to market
- Already approved and long off-patent; the brand is superseded by generic valsartan from multiple manufacturers.
- Why 1/10
- No hard, dated catalyst is scheduled in the next ~12 months: Diovan/valsartan is a fully genericized, off-patent molecule with no Novartis-sponsored development, no pending FDA decision, and no catalyst records, the defining binaries (original approval and the patent cliff) passed years ago, so the drug can drive essentially no share-price move at a mega-cap like NVS.
There is nothing to trade on Diovan itself, it is a generic commodity now. Investors watching Novartis should ignore this molecule and instead track the cardiovascular franchise via the sacubitril/valsartan combination (a separate product) plus pending pipeline readouts (e.g., BION-1301, iptacopan) that actually move NVS. Current NVS setup: price ~$156.24, analyst recommendation "hold" with mean target $157.15 (implied upside ~2.5%).
Price Chart
Executive Summary
Diovan (valsartan) is Novartis's once-blockbuster blood-pressure medicine, now a fully genericized legacy brand: the FDA action records in this session show only generic manufacturers (Ohm Laboratories, Umedica Laboratories) actively labeling valsartan and valsartan-combination products in 2026, and no FDA catalyst, press release, or Novartis-sponsored trial exists for the drug. At a ~$156 stock with a "hold" consensus and a pipeline focused on newer drugs, Diovan is immaterial to NVS's valuation.
How It Works
Valsartan is an angiotensin II receptor blocker (ARB): it blocks a hormone that constricts blood vessels, letting them relax and lowering blood pressure. It was a once-blockbuster Novartis blood-pressure pill (Diovan), but the molecule is now off-patent and sold as cheap generics.
Trial Status
No Novartis-sponsored trials for Diovan/valsartan appear in the local pipeline data; the molecule shows up only as generic valsartan used as comparator/background therapy in hypertension studies (e.g., NCT07700875, valsartan 160 mg in essential hypertension) or inside the separate sacubitril/valsartan combination product. FDA records show only routine safety-labeling updates (fetal-toxicity boxed warning) from generic ANDA holders Ohm Laboratories (ANDA077492) and Umedica Laboratories (ANDA219946) dated July–August 2026.
The Two-Sided Case
Upcoming Catalysts
- None for Diovan/valsartan, no regulatory or clinical events scheduled.
- Context for NVS shareholders (not Diovan): results-pending readouts flagged in local data include BION-1301 (Phase 2 IgA nephropathy) and iptacopan (Phase 3 aHUS); NVS also carries elevated FINRA short-volume flow (~55–58% short ratio on recent off-exchange sessions).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVARTIS AG 6-K NVS ·Originating report